Intrinsic value of Dentsply Sirona - XRAY

Previous Close

$57.67

  Intrinsic Value

$37.99

stock screener

  Rating & Target

sell

-34%

Previous close

$57.67

 
Intrinsic value

$37.99

 
Up/down potential

-34%

 
Rating

sell

We calculate the intrinsic value of XRAY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  40.05
  5.80
  5.72
  5.65
  5.58
  5.52
  5.47
  5.43
  5.38
  5.34
  5.31
  5.28
  5.25
  5.23
  5.20
  5.18
  5.16
  5.15
  5.13
  5.12
  5.11
  5.10
  5.09
  5.08
  5.07
  5.06
  5.06
  5.05
  5.05
  5.04
  5.04
Revenue, $m
  3,745
  3,962
  4,189
  4,425
  4,673
  4,931
  5,200
  5,483
  5,778
  6,087
  6,410
  6,748
  7,102
  7,474
  7,862
  8,270
  8,697
  9,145
  9,614
  10,107
  10,623
  11,164
  11,732
  12,328
  12,953
  13,609
  14,297
  15,020
  15,778
  16,573
  17,408
Variable operating expenses, $m
 
  3,373
  3,532
  3,698
  3,871
  4,052
  4,241
  4,439
  4,646
  4,862
  5,089
  4,731
  4,979
  5,239
  5,512
  5,798
  6,097
  6,411
  6,740
  7,085
  7,447
  7,827
  8,225
  8,643
  9,081
  9,541
  10,023
  10,530
  11,061
  11,619
  12,204
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,291
  3,373
  3,532
  3,698
  3,871
  4,052
  4,241
  4,439
  4,646
  4,862
  5,089
  4,731
  4,979
  5,239
  5,512
  5,798
  6,097
  6,411
  6,740
  7,085
  7,447
  7,827
  8,225
  8,643
  9,081
  9,541
  10,023
  10,530
  11,061
  11,619
  12,204
Operating income, $m
  455
  589
  657
  728
  802
  879
  959
  1,044
  1,132
  1,224
  1,321
  2,017
  2,123
  2,234
  2,350
  2,472
  2,600
  2,734
  2,874
  3,021
  3,175
  3,337
  3,507
  3,685
  3,872
  4,068
  4,274
  4,490
  4,716
  4,954
  5,204
EBITDA, $m
  727
  1,283
  1,356
  1,433
  1,513
  1,596
  1,683
  1,775
  1,870
  1,970
  2,075
  2,184
  2,299
  2,419
  2,545
  2,677
  2,815
  2,960
  3,112
  3,272
  3,439
  3,614
  3,798
  3,991
  4,193
  4,405
  4,628
  4,862
  5,107
  5,365
  5,635
Interest expense (income), $m
  37
  53
  60
  67
  75
  83
  91
  99
  108
  118
  128
  138
  149
  160
  172
  185
  198
  211
  226
  241
  256
  273
  290
  308
  327
  347
  368
  390
  413
  438
  463
Earnings before tax, $m
  441
  536
  597
  661
  727
  796
  869
  944
  1,024
  1,106
  1,193
  1,879
  1,974
  2,074
  2,178
  2,288
  2,402
  2,522
  2,649
  2,781
  2,919
  3,065
  3,217
  3,377
  3,545
  3,721
  3,906
  4,100
  4,303
  4,517
  4,741
Tax expense, $m
  10
  145
  161
  178
  196
  215
  235
  255
  276
  299
  322
  507
  533
  560
  588
  618
  649
  681
  715
  751
  788
  827
  869
  912
  957
  1,005
  1,055
  1,107
  1,162
  1,220
  1,280
Net income, $m
  430
  392
  436
  482
  531
  581
  634
  689
  747
  808
  871
  1,372
  1,441
  1,514
  1,590
  1,670
  1,754
  1,841
  1,933
  2,030
  2,131
  2,237
  2,348
  2,465
  2,588
  2,716
  2,851
  2,993
  3,141
  3,297
  3,461

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  385
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  11,556
  11,827
  12,504
  13,210
  13,948
  14,718
  15,524
  16,366
  17,247
  18,169
  19,133
  20,144
  21,201
  22,309
  23,470
  24,687
  25,961
  27,298
  28,699
  30,169
  31,710
  33,326
  35,022
  36,800
  38,666
  40,624
  42,679
  44,835
  47,098
  49,472
  51,964
Adjusted assets (=assets-cash), $m
  11,171
  11,827
  12,504
  13,210
  13,948
  14,718
  15,524
  16,366
  17,247
  18,169
  19,133
  20,144
  21,201
  22,309
  23,470
  24,687
  25,961
  27,298
  28,699
  30,169
  31,710
  33,326
  35,022
  36,800
  38,666
  40,624
  42,679
  44,835
  47,098
  49,472
  51,964
Revenue / Adjusted assets
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
  0.335
Average production assets, $m
  2,059
  2,179
  2,304
  2,434
  2,570
  2,712
  2,860
  3,015
  3,178
  3,348
  3,525
  3,711
  3,906
  4,110
  4,324
  4,548
  4,783
  5,030
  5,288
  5,559
  5,843
  6,140
  6,453
  6,780
  7,124
  7,485
  7,864
  8,261
  8,678
  9,115
  9,574
Working capital, $m
  976
  646
  683
  721
  762
  804
  848
  894
  942
  992
  1,045
  1,100
  1,158
  1,218
  1,282
  1,348
  1,418
  1,491
  1,567
  1,647
  1,732
  1,820
  1,912
  2,009
  2,111
  2,218
  2,330
  2,448
  2,572
  2,701
  2,838
Total debt, $m
  1,532
  1,709
  1,916
  2,132
  2,358
  2,594
  2,840
  3,098
  3,368
  3,650
  3,945
  4,254
  4,578
  4,917
  5,272
  5,644
  6,034
  6,443
  6,872
  7,322
  7,793
  8,288
  8,807
  9,351
  9,922
  10,521
  11,150
  11,810
  12,502
  13,228
  13,991
Total liabilities, $m
  3,442
  3,619
  3,826
  4,042
  4,268
  4,504
  4,750
  5,008
  5,278
  5,560
  5,855
  6,164
  6,488
  6,827
  7,182
  7,554
  7,944
  8,353
  8,782
  9,232
  9,703
  10,198
  10,717
  11,261
  11,832
  12,431
  13,060
  13,720
  14,412
  15,138
  15,901
Total equity, $m
  8,114
  8,208
  8,678
  9,168
  9,680
  10,215
  10,774
  11,358
  11,969
  12,609
  13,279
  13,980
  14,714
  15,483
  16,288
  17,132
  18,017
  18,945
  19,917
  20,937
  22,007
  23,128
  24,305
  25,539
  26,835
  28,193
  29,619
  31,115
  32,686
  34,334
  36,063
Total liabilities and equity, $m
  11,556
  11,827
  12,504
  13,210
  13,948
  14,719
  15,524
  16,366
  17,247
  18,169
  19,134
  20,144
  21,202
  22,310
  23,470
  24,686
  25,961
  27,298
  28,699
  30,169
  31,710
  33,326
  35,022
  36,800
  38,667
  40,624
  42,679
  44,835
  47,098
  49,472
  51,964
Debt-to-equity ratio
  0.189
  0.210
  0.220
  0.230
  0.240
  0.250
  0.260
  0.270
  0.280
  0.290
  0.300
  0.300
  0.310
  0.320
  0.320
  0.330
  0.330
  0.340
  0.350
  0.350
  0.350
  0.360
  0.360
  0.370
  0.370
  0.370
  0.380
  0.380
  0.380
  0.390
  0.390
Adjusted equity ratio
  0.692
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694
  0.694

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  430
  392
  436
  482
  531
  581
  634
  689
  747
  808
  871
  1,372
  1,441
  1,514
  1,590
  1,670
  1,754
  1,841
  1,933
  2,030
  2,131
  2,237
  2,348
  2,465
  2,588
  2,716
  2,851
  2,993
  3,141
  3,297
  3,461
Depreciation, amort., depletion, $m
  272
  693
  699
  705
  711
  717
  724
  731
  738
  746
  754
  167
  176
  185
  195
  205
  215
  227
  238
  250
  263
  277
  291
  305
  321
  337
  354
  372
  391
  411
  431
Funds from operations, $m
  520
  1,085
  1,135
  1,187
  1,242
  1,299
  1,358
  1,420
  1,486
  1,554
  1,625
  1,539
  1,617
  1,699
  1,785
  1,875
  1,969
  2,068
  2,172
  2,280
  2,394
  2,514
  2,639
  2,771
  2,909
  3,053
  3,205
  3,365
  3,532
  3,708
  3,892
Change in working capital, $m
  -43
  35
  37
  39
  40
  42
  44
  46
  48
  50
  53
  55
  58
  61
  63
  66
  70
  73
  77
  80
  84
  88
  93
  97
  102
  107
  112
  118
  124
  130
  136
Cash from operations, $m
  563
  1,049
  1,098
  1,149
  1,201
  1,257
  1,314
  1,374
  1,437
  1,503
  1,572
  1,484
  1,559
  1,639
  1,722
  1,808
  1,900
  1,995
  2,095
  2,200
  2,310
  2,425
  2,547
  2,674
  2,807
  2,947
  3,093
  3,247
  3,409
  3,578
  3,756
Maintenance CAPEX, $m
  0
  -93
  -98
  -104
  -110
  -116
  -122
  -129
  -136
  -143
  -151
  -159
  -167
  -176
  -185
  -195
  -205
  -215
  -227
  -238
  -250
  -263
  -277
  -291
  -305
  -321
  -337
  -354
  -372
  -391
  -411
New CAPEX, $m
  -126
  -120
  -125
  -130
  -136
  -142
  -148
  -155
  -162
  -170
  -178
  -186
  -195
  -204
  -214
  -224
  -235
  -246
  -258
  -271
  -284
  -298
  -312
  -328
  -344
  -361
  -379
  -397
  -417
  -438
  -459
Cash from investing activities, $m
  60
  -213
  -223
  -234
  -246
  -258
  -270
  -284
  -298
  -313
  -329
  -345
  -362
  -380
  -399
  -419
  -440
  -461
  -485
  -509
  -534
  -561
  -589
  -619
  -649
  -682
  -716
  -751
  -789
  -829
  -870
Free cash flow, $m
  623
  837
  875
  915
  956
  999
  1,044
  1,090
  1,139
  1,190
  1,244
  1,139
  1,197
  1,258
  1,322
  1,390
  1,460
  1,533
  1,610
  1,691
  1,776
  1,864
  1,958
  2,055
  2,158
  2,265
  2,377
  2,496
  2,620
  2,750
  2,886
Issuance/(repayment) of debt, $m
  299
  198
  207
  216
  226
  236
  246
  258
  270
  282
  295
  309
  324
  339
  355
  372
  390
  409
  429
  450
  472
  495
  519
  544
  571
  599
  629
  660
  692
  727
  763
Issuance/(repurchase) of shares, $m
  -773
  67
  34
  8
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -461
  265
  241
  224
  226
  236
  246
  258
  270
  282
  295
  309
  324
  339
  355
  372
  390
  409
  429
  450
  472
  495
  519
  544
  571
  599
  629
  660
  692
  727
  763
Total cash flow (excl. dividends), $m
  164
  1,101
  1,116
  1,139
  1,182
  1,235
  1,290
  1,348
  1,409
  1,472
  1,539
  1,448
  1,521
  1,598
  1,678
  1,762
  1,850
  1,942
  2,039
  2,141
  2,247
  2,359
  2,476
  2,599
  2,729
  2,864
  3,006
  3,155
  3,312
  3,476
  3,649
Retained Cash Flow (-), $m
  -5,776
  -458
  -470
  -490
  -512
  -535
  -559
  -584
  -611
  -640
  -670
  -701
  -734
  -769
  -806
  -844
  -885
  -928
  -973
  -1,020
  -1,069
  -1,122
  -1,177
  -1,234
  -1,295
  -1,359
  -1,426
  -1,496
  -1,570
  -1,648
  -1,730
Prev. year cash balance distribution, $m
 
  364
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  1,007
  646
  648
  670
  700
  731
  764
  797
  833
  869
  747
  787
  829
  872
  918
  965
  1,015
  1,067
  1,121
  1,178
  1,237
  1,300
  1,365
  1,433
  1,505
  1,580
  1,659
  1,742
  1,828
  1,919
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  966
  592
  564
  551
  542
  531
  516
  498
  478
  456
  355
  336
  315
  293
  269
  245
  221
  196
  173
  150
  128
  108
  89
  73
  59
  46
  36
  27
  20
  14
Current shareholders' claim on cash, %
  100
  99.5
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2
  99.2

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.

FINANCIAL RATIOS  of  Dentsply Sirona (XRAY)

Valuation Ratios
P/E Ratio 30.9
Price to Sales 3.5
Price to Book 1.6
Price to Tangible Book
Price to Cash Flow 23.6
Price to Free Cash Flow 30.4
Growth Rates
Sales Growth Rate 40.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 75%
Cap. Spend. - 3 Yr. Gr. Rate 4.5%
Financial Strength
Quick Ratio 18
Current Ratio 0
LT Debt to Equity 18.6%
Total Debt to Equity 18.9%
Interest Coverage 13
Management Effectiveness
Return On Assets 5.8%
Ret/ On Assets - 3 Yr. Avg. 6.6%
Return On Total Capital 6.5%
Ret/ On T. Cap. - 3 Yr. Avg. 7.4%
Return On Equity 8.2%
Return On Equity - 3 Yr. Avg. 10.8%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 53.4%
Gross Margin - 3 Yr. Avg. 55%
EBITDA Margin 20%
EBITDA Margin - 3 Yr. Avg. 19.6%
Operating Margin 12.1%
Oper. Margin - 3 Yr. Avg. 13.8%
Pre-Tax Margin 11.8%
Pre-Tax Margin - 3 Yr. Avg. 12.6%
Net Profit Margin 11.5%
Net Profit Margin - 3 Yr. Avg. 10.6%
Effective Tax Rate 2.3%
Eff/ Tax Rate - 3 Yr. Avg. 15.2%
Payout Ratio 15.1%

XRAY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the XRAY stock intrinsic value calculation we used $3745 million for the last fiscal year's total revenue generated by Dentsply Sirona. The default revenue input number comes from 2016 income statement of Dentsply Sirona. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our XRAY stock valuation model: a) initial revenue growth rate of 5.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for XRAY is calculated based on our internal credit rating of Dentsply Sirona, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Dentsply Sirona.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of XRAY stock the variable cost ratio is equal to 86%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for XRAY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Dentsply Sirona.

Corporate tax rate of 27% is the nominal tax rate for Dentsply Sirona. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the XRAY stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for XRAY are equal to 55%.

Life of production assets of 22.2 years is the average useful life of capital assets used in Dentsply Sirona operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for XRAY is equal to 16.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $8114 million for Dentsply Sirona - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 231.809 million for Dentsply Sirona is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Dentsply Sirona at the current share price and the inputted number of shares is $13.4 billion.

RELATED COMPANIES Price Int.Val. Rating
ALGN Align Technolo 265.07 259.38  hold
BIOL Biolase 0.420 0.06  str.sell
MLSS Milestone Scie 0.900 0.07  str.sell
DHR Danaher 99.33 56.91  sell
MMM 3M 237.02 160.70  sell

COMPANY NEWS

▶ Daniel Loeb's Top 10 Holdings of 4th Quarter   [Feb-19-18 05:57PM  GuruFocus.com]
▶ Daniel Loeb's Top 10 Holdings of 4th Quarter   [05:49PM  GuruFocus.com]
▶ Dentsply Sirona Declares Quarterly Cash Dividend   [Feb-14-18 05:00PM  GlobeNewswire]
▶ Juno and Boeing climb while Goldman Sachs and GE drop   [Jan-17-18 04:35PM  Associated Press]
▶ Why eBay and Dentsply Sirona Fell on January 10   [Jan-12-18 09:02AM  Market Realist]
▶ Wall Street Issues Majority Buy Ratings on Align Technology   [Jan-03-18 10:32AM  Market Realist]
▶ Dentsply Sirona Declares Quarterly Cash Dividend   [Dec-12-17 05:00PM  GlobeNewswire]
▶ With Innovation Booming, Dental Stocks Will Make You Smile   [Dec-05-17 02:18PM  GuruFocus.com]
▶ Weekly CFO Buys Highlight   [Nov-25-17 03:34PM  GuruFocus.com]
▶ Dentsply Sirona Sees Relative Strength Rating Rise To 72   [03:00AM  Investor's Business Daily]
▶ Stock Market News For Nov 6, 2017   [Nov-06-17 10:02AM  Zacks]
▶ AIG and Pandora skid while Apple and Dentsply rise   [Nov-03-17 04:52PM  Associated Press]
▶ Dentsply tops Street 3Q forecasts   [07:20AM  Associated Press]
▶ Mass confusion over Obamacare plans   [Oct-20-17 10:11AM  Yahoo Finance Video]
▶ [$$] Behind Unusual Ouster of Company's Top Three Leaders: A Soured Merger   [Oct-03-17 01:10PM  The Wall Street Journal]
▶ A Kick in the Teeth from Dentsply   [12:44PM  The Wall Street Journal]
▶ Dentsply Sirona Announces Leadership Changes   [07:30AM  GlobeNewswire]
▶ Dentsply Sirona Stock Recovering from Recent 52-Week Low   [Sep-25-17 10:39AM  Market Realist]
▶ New Strong Sell Stocks for September 12th   [Sep-12-17 08:22AM  Zacks]
▶ Discussing Dentsply Sironas Recent Stock Performance   [Aug-17-17 10:37AM  Market Realist]
▶ Dentsply Sironas Technologies Segment Sales Declined in 2Q17   [Aug-16-17 10:37AM  Market Realist]
▶ Dentsply Sironas 2Q17 Results: Key Highlights   [07:37AM  Market Realist]
Financial statements of XRAY
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.